Head-to-head · WeighScore
Found vs Oak
By GLP-1 ScorecardUpdated
Score comparison
Found has the higher recorded score — 83.5/100 to 63.2/100.
Found grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Found offers compounded, brand-name and oral GLP-1 routes, but their bills differ: compounded plans include medication and care, while branded medication and labs cost extra.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Found | Oak |
|---|---|---|
| WeighScore | 83.5/100 | 63.2/100 |
| Grade | B | C |
| Site position | #8 | #221 |
| Semaglutide | $179 first, then $289 every 28 days on the one-term cash compounded plan (labs extra; confirm selected terms) | From $119/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified |
| Tirzepatide | $219 first, then $359 every 28 days on the one-term cash compounded plan (labs extra; confirm selected terms) | From $185/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified |
| Coverage | U.S. service with state, treatment and insurance restrictions; confirm your eligibility | Confirm selected treatment and state: homepage promotes a 50-state provider network, while terms say 45 states or certain states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Site position #8 · B
Strengths
- Current compounded offers include medication, membership and care, with separate semaglutide and tirzepatide price tables
- Branded injection and oral options are listed, subject to prescription, stock and patient-specific terms
- Insurance-track clinical visits and cash-pay care are distinguished in the public billing documents
- Terms name possible independent medical groups and describe check-ins and messaging
What to consider
- Cash compounded renewal rates differ by molecule and recur every 28 days, not a calendar month
- Longer-term advertised rates and upfront-payment wording do not settle the selected charge or supply
- Labs cost extra; insurance-track cost-sharing can add to the bill and does not reimburse compounded-medication fees
- Refund wording about three days and the first consultation conflicts; rejection of a preferred GLP-1 is not disqualification from all treatment
- The assigned compounder, actual treating practice and individual license status remain unresolved
- A brand or oral menu listing does not establish a specific available prescription, complete price or clinical equivalence
Site position #221 · C
Strengths
- Current semaglutide and tirzepatide product pages explicitly identify the twelve-month term behind advertised starting rates
- Monthly and three-month plans have no cancellation fee before the next charge under the current refund section
- The policy specifies a medical-stop exception, prepaid future-month refund calculation and a limit on quarterly-plan discount repayment
- Branded pens and Oral Wegovy tablets are now advertised alongside compounded injections; availability and exact prices require confirmation
What to consider
- The $119/$185 rates do not establish a monthly debit, dose-independent price or usable shipment supply
- Leaving a six- or twelve-month quarterly plan early can repay discounts on months received, capped at one quarterly payment
- Orders already sent to the pharmacy are final; stopping the account does not refund them
- The same terms page retains inconsistent company names, membership-fee language and state-availability statements
- The public material reviewed did not establish the assigned medical practice, individual prescriber or dispensing pharmacy legal name and address
Featured provider
Found
Found scores 83.5/100 (B). Found offers compounded, brand-name and oral GLP-1 routes, but their bills differ: compounded plans include medication and care, while branded medication and labs cost extra.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.